Weekly paclitaxel (WP) +/-bevacizumab (B) in angiosarcoma (AS) patients (pts): Analysis of prognostic/predictive factors from a randomized phase 2 trial

This article has no abstract
Epistemonikos ID: 900971a9ae189400e214400fd0e0d9b48d02e69d
First added on: Feb 08, 2025